No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:43:09.131Z. Latest historical point 2024-11-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Sagimet Biosciences Inc. (SGMT) stock was $8.77 as of Oct 6, 2026, 2:40 PM EDT, down 2.93% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +23.7% · 3-year avg +7.9%/yr
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Biotechnology · San Mateo, CA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.25
Revenue Est.
$166667.00
Last Quarter Results
EPS
$-0.26
vs Estimate
$-0.27
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SGMT | $285.58M | $8.77 | -2.93% | +23.74% | N/A | N/A | N/A |
| 2ABEO | $285.83M | $5.01 | -1.86% | -5.53% | -26.46% | -29.45% | vs SGMT |
| 3LAB | $286.36M | $0.73 | -4.13% | -42.91% | -32.98% | -20.93% | vs SGMT |
| 4BBOT | $283.58M | $3.54 | -1.67% | -70.70% | N/A | N/A | vs SGMT |
| 5ACB | $282.46M | $4.56 | +2.24% | -20.97% | -42.83% | -30.23% | vs SGMT |
| 6FULC | $281.92M | $3.69 | -0.40% | -59.59% | -31.70% | N/A | vs SGMT |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 11 analysts
Average Price Target
$27.91
+218.4% upside
Low
$7.00
Current
$8.77
High
$56.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.29 | $-0.26 | $-0.21 | 7 |
| Quarter ending Dec 2026 | $-0.31 | $-0.28 | $-0.21 | 7 |
| Quarter ending Mar 2027 | $-0.31 | $-0.31 | $-0.31 | 2 |
| Quarter ending Jun 2027 | $-0.34 | $-0.34 | $-0.34 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.42 | $-1.13 | $-0.92 | 8 |
| FY 2027 | $-2.07 | $-1.34 | $-0.48 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $166667.00 | $166667.00 | $166667.00 | 4 |
| Quarter ending Dec 2026 | $166667.00 | $166667.00 | $166667.00 | 5 |
| Quarter ending Mar 2027 | $1.36M | $1.36M | $1.36M | 4 |
| Quarter ending Jun 2027 | $420000.00 | $420000.00 | $420000.00 | 5 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $111111.00 | $111111.00 | $111111.00 | 7 |
| FY 2027 | $8.13M | $8.13M | $8.13M | 7 |
